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Abstract 
Protein Kinase C (PKC), a member of isozyme family plays an important role in cell growth regulation and differentiation and is 
being considered as a novel target of many anti-cancer drugs. In this study we have explored the affinity and interaction of 
some natural plant derived compounds against PKCα to find out some important active site amino acid residues that play an 
important role in the binding of inhibitors with the active site. 
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Introduction 
Protein kinase C is a member of an eleven 
mammalian isozyme family that plays an important role 
in cell growth regulation and differentiation. Protein 
kinases are enzymes which catalyses the transfer of 
phosphate from adenosine-5’-triphosphate to amino 
acids residues in certain proteins. Most protein kinase 
inhibitors are directed towards the ATP-binding site. 
Recent research reveals that these inhibitors must 
discriminate between ATP-binding sites of all protein 
kinases as well as other proteins that also utilize ATP. 
It is therefore beneficial to target protein kinases other 
than the ATP-binding site (Bogoyevitch et al., 2005). 
The central role of PKC in cellular signal 
transduction has made it an important therapeutic 
target for cancer especially prostate cancer. The 
targeting of PKC with some natural compounds like 
nimbolide, EGCG, curcumin, allicin, capsaicin, eugenol, 
cinnamaldehyde and farnesol may be an important 
step to provide an insight into its active site along with 
the efficacies of inhibitors. The aim of this work is to 
explore the affinity and interaction of some natural 
compounds against PKCα. In this study we have made 
an attempt to block diseases caused by abnormalities 
in these signaling pathways by using some selected 
natural inhibitors that are considered to be effective 
against cancer. The inhibitors taken for this study are 
well known natural compounds extracted from different 
plants. 
 
 
 
 
Material and Methods 
 
Natural Compounds used for Study:  Nimbolide, 
Epigallocatechin Gallate (EGCG), Curcumin, Allicin, 
Capsaicin, Eugenol, Cinnamaldehyde and Farnesol. 
 
Protein preparation: The crystal structure of PKCα 
taken in this study was extracted from protein data 
bank and all the HETATMS were removed. The protein 
was subjected to two steps energy minimization to 
remove the bad steric clashes using steepest descent 
and conjugate gradient methods for 1000 steps at RMS 
gradient of 0.1 and 0.05 respectively. During the 
energy minimization process the backbone were fixing 
the backbone. 
 
Ligands preparations: The three dimensional 
structures of the natural inhibitors taken in this study 
were extracted from Pubchem compounds database. 
Char MM force field (Brooks et al., 2009) was applied 
to them and further, was subjected to single step 
minimization using steepest descent method for 500 
steps at RMS gradient of 0.01. 
 
Docking: All the natural inhibitors taken for the study 
were subjected to dock within the active site of PKCα 
using LigandFit (Venkatachalam et al., 2003) docking 
program available with DS2.5, Site 2 was selected 
consisting of 1156 points and partition level was set to 
5. For docking Number of Monte Carlo steps was set to 
"2 500 120,4 1200 300,6 1500 350,10 2000 500,25 
3000 750" with maximum 10 number of poses. 
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Dock Analyses: All the docked inhibitors were 
analyzed on the basis of Dock score generated by 
LigandFit. 
 
Docking Validation: To validate the docking program 
we again docked the inhibitor present within the active 
site of PKCα using the same parameters used for 
docking natural inhibitors into its active site.  
 
Result and Discussion 
Among all the natural inhibitors docked, EGCG 
was found to bind with the best efficacy. Curcumin and 
allicin were also effective. All the comparison was 
made on the basis of dock score given by LigandFit. 
The importance of natural inhibitors against cancer is 
well known. So, it was important to explore the mode of 
interaction of these inhibitors against the target enzyme. 
Epigallocatechin gallate (EGCG) a compound derived 
from green tea shows promising response and can be 
used as a potent inhibitor against PKCα for curing 
cancer. There are some other compounds revealed by 
this study that could be used as potent inhibitors 
against cancer. Most of the protein kinase inhibitors are 
directed towards the ATP-binding site. Recent research 
reveals that they must discriminate between ATP-
binding sites of all protein kinases as well as the other 
proteins that also utilize ATP (Toledo et al., 1999 and 
Morin et al., 2000). It is therefore beneficial to target 
protein kinases other than the ATP-binding site 
(Bogoyevitch et al., 2005 and Mukherjee et al., 2009). 
Reports exist which indicates that the overexpression 
of PKC causes transformation of cancer cell lines 
(Mischak et al., 1993).  
Some amino acid residues were found to play an 
important role in the binding of inhibitors within the 
active site of PKCα. M417 was involved in making 
hydrophobic contacts in all the cases, and is presumed 
to be a key player. The other amino acids that actively 
participated include A366, V420, A480 and D481. 
Among these V420 was making maximum number of 
hydrogen bonds with the inhibitors followed by D467, 
D481 and Q387 (Table-1). These residues along with 
others were also actively involved in forming 
hydrophobic contacts (Fig 1A-D). 
To confirm the accuracy of the docking program 
as well as the parameters used for docking, the 
inhibitor from our parent molecule (pdb id: 3IW4) was 
extracted and again subjected to dock within the active 
site using the same parameters as that taken for 
docking the natural compounds. It was found that the 
binding orientation of the ligand was same as that in 
the parent molecule. This confirmed the accuracy of 
binding and docking program used. Fig 2 shows 
comparison between the binding modes of inhibitor as 
within the x-ray structure (shown in red) as well as 
found after the re-dock (shown in blue), both were 
found to bind in the same orientation.
 
Figure 1 (A-D): 2D representation of the top four docked ligands within the active site of PKCα. Fig 1(A) Binding orientation of EGCG within 
the active site of PKCα. Fig 1(B) Binding orientation of Curcumin within the active site of PKCα. Fig 1(C) Binding orientation of Allicin within 
the active site of PKCα. Fig 1(D) Binding orientation of Capsaicin within the active site of PKCα 
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Figure 2: Binding orientation of the inhibitor already present within the active site of PKCα (in red) and that after re-docking the same with 
LigandFit docking program (Blue) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table1: Dock Scores of natural compounds with target enzyme PKC along with details of the residues involved in binding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
This study shows the effectiveness of natural 
compounds that can further be studied as potential 
anticancerous drugs. It also shows the scope of other 
natural compounds that have not yet been explored. 
The role of some crucial amino acids involved in proper 
binding of inhibitors with the active site of PKCα can be 
useful for designing better drugs to combat cancer. 
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